KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:开放图源暂不可得 入排置信度 0.98

Comparability of aflibercept biosimilar with reference aflibercept in diabetic macular edema: subgroup analysis of the pivotal Phase-III INSIGHT randomized clinical trial.

Susan B Bressler, Piotr Oleksy, Daniel Virgil Alfaro, Rajendra S Apte, Abhijit Barve, Kristine Baumane, Katrin Beckmann, Rozsa Degi, Jan Ernest, Vishali Gupta, Motohiro Kamei, Genichiro Kishino, Katrin Lorenz, Dennis M Marcus, Debdipta Bose, Prasanna C Ganapathi, Subramanian Loganathan

Expert Opin Biol Ther 26(5) 525-534

PMID42104207
PMCID-
DOI10.1080/14712598.2026.2672422
发表日期2026-05-08
入排依据:未发现恶性肿瘤人群证据。
PubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。
摘要

摘要

BACKGROUND: Phase-III INSIGHT study subgroup analyses observed best corrected visual acuity (BCVA) and central subfield thickness (CST) outcomes at Week 8/52 in diabetic macular edema treated with aflibercept biosimilar (MYL-1701P/Yesafili™) or reference aflibercept (Eylea®). RESEARCH DESIGN AND METHODS: Two mg (0.05 mL) MYL-1701P (N = 179) or reference aflibercept (N = 176) was given intravitreally every 4 weeks for 5 doses, followed by 8-weekly dosing through Week 48. Subgroups were stratified by baseline BCVA/baseline CST/age/gender/race/ethnicity/region/glycated hemoglobin (HbA1c)/anti-drug antibody status/anti-vascular endothelial growth factor therapy in fellow eye. Main outcome measures included mean change in BCVA/CST from baseline to Week 8/52 with 90% confidence interval (CI). RESULTS: For MYL-1701P and reference aflibercept, participants with baseline BCVA score (73-55 letters) had an adjusted mean difference of 0.03 letters in BCVA (90% CI: -1.26,1.31) and 15.46 µm in CST (90% CI: -0.02,30.93) at 8 weeks and 0.81 letters in BCVA (90% CI: -0.58,2.2) and 6.41 µm in CST (90% CI: 17.31,30.12) at 52 weeks. Subgroup categories with ≥45% participants, including CST (<400/≥400 µm) and HbA1c (<8%/>8%) had an adjusted mean difference within -3 to 3 letters (90% CI) in BCVA at 8/52 weeks. CONCLUSIONS: The exploratory subgroup analyses supported clinical equivalence between MYL-1701P and reference aflibercept showing clinically comparable changes in BCVA/CST across most subgroups. TRIAL REGISTRATION: ClinicalTrials.gov identifier is NCT03610646.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。